ANTI-MULLERIAN HORMONE AND INHIBIN B AS A DIAGNOSTIC REPLACEMENT OF HUMAN CHORIONIC GONADOTROPIN STIMULATION TEST IN EVALUATION OF 46 XY DISORDERS OF SEX DEVELOPMENT
Main Article Content
Keywords
46 XY DSD, inhibin B, anti-Mullerian hormone (AMH), testosterone
Abstract
Background: As blood anti-Müllerian hormone (AMH) measurement may assess male gonad function without the need of invasive dynamic testing, it is becoming more and more common. A measurement of inhibin B may be thought of as a diagnosis tool that provides accurate data regarding the existence and functionality of the tests.
Objective: To assess the role of AMH and inhibin-B in diagnosis of 46, XY disorders of sex development (DSD) in comparison to HCG stimulation test.
Patients and methods: 42 individuals with 46 XY DSD were the subject of the research, which also included 42 healthy male participants from DEMPU, New Pediatric Hospital, and Cairo University. The analyzed patients had a 4 year average age.
Results: there was a statistically considerable variation between level of AMH in testicular agenesis/dysgenesis and 46 XY DSD group (p˂0.001). Basal AMH and HCG-activated testosterone and DHT showed a substantial connection. Inhibin B, HCG-stimulated testosterone, and DHT were not shown to be substantially connected with one another. At a cut-off value of (43.2ng/ml), the sensitivity of AMH was (90.9%), specificity (96.8%), NPV (90.91%) PPV (96.77%), with overall accuracy (95.24%) to determine if functioning testicular tissue is present. While the inhibin B showed no discrimination between subjects who had functioning testicular tissue from those who had not.
Conclusion: AMH is valuable reliable non-invasive parameter for identifying functional testicular tissue in 46 XY DSD patients.
References
2. Ahmed, S., Cheng, A, & Hughes, I. (1999). Assessment of the gonadotrophin–gonadal axis in androgen insensitivity syndrome. Archives of disease in childhood, 80(4), 324-329.
3. Aksglaede, L., Sørensen, K., Boas, M., Mouritsen, A., Hagen, C., Jensen, R., Main, K. (2010). Changes in anti-Mullerian hormone (AMH) throughout the life span: a population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. The Journal of Clinical Endocrinology & Metabolism, 95(12), 5357-5364.
4. Andersson, A.M. & Skakkebæk, N.E. (2001). Serum inhibin B levels during male childhood and puberty. Molecular and cellular endocrinology, 180(1-2), 103-107.
5. Babbar, P. & Shah, A. (2019). Disorders of Sexual Development. Comprehensive Care of the Transgender Patient E-Book, 25.
6. Bennecke, E., Köhler, B., Röhle, R., Thyen, U., Gehrmann, K., Lee, P., Wiesemann, C. (2020). Disorders or Differences of Sex Development? Views of Affected Individuals on DSD Terminology. The Journal of Sex Research, 1-10.
7. Bergada, I., Bergada, C. & Campo, S. (2001). Role of inhibins in childhood and puberty. Journal of Pediatric Endocrinology and Metabolism, 14(4), 343-354.
8. Buonocore, F., Clifford-Mobley, O., King, T.F., Striglioni, N., Man, E., Suntharalingham, J.P., Rumsby, G. (2019). Next-generation sequencing reveals novel genetic variants (SRY, DMRT1, NR5A1, DHH, DHX37) in adults with 46, XY DSD. Journal of the Endocrine Society, 3(12), 2341-2360.
9. Crofton, P., Evans, A., Groome, N.P., Taylor, M., Holland, C. & Kelnar, C. (2002). Inhibin B in boys from birth to adulthood: relationship with age, pubertal stage, FSH and testosterone. Clinical endocrinology, 56(2), 215-221.
10. Ekenze, S., Nwangwu, E., Amah, C., Agugua-Obianyo, N., Onuh, A. & Ajuzieogu, O. (2015). Disorders of sex development in a developing country: perspectives and outcome of surgical management of 39 cases. Pediatric surgery international, 31(1), 93-99.
11. Freire, A.V., Grinspon, R.P. & Rey, R.A. (2018). Importance of serum testicular protein hormone measurement in the assessment of disorders of sex development. Sexual Development, 12(1-3), 30-40.
12. Grinspon, R.P. & Rey, R.A. (2010). Anti-müllerian hormone and sertoli cell function in paediatric male hypogonadism. Hormone Research in Paediatrics, 73(2), 81-92.
13. Grinspon, R.P., Ropelato, M.G., Bedecarrás, P., Loreti, N., Ballerini, M. G., Gottlieb, S., Rey, R.A. (2012). Gonadotrophin secretion pattern in anorchid boys from birth to pubertal age: pathophysiological aspects and diagnostic usefulness. Clinical endocrinology, 76(5), 698-705.
14. Hafez, M., Abd El Dayem, S.M., El Mougy, F., Atef, A., Kandil, M. & Galal, A. (2014). The role of anti-Mullerian and inhibin B hormones in the evaluation of 46, XY disorders of sex development. Journal of Pediatric Endocrinology and Metabolism, 27(9-10), 891-899.
15. Josso, N., Rey, R.A., & Picard, J.Y. (2013). Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist. International journal of endocrinology, 2013.
16. Kubini, K., Zachmann, M., Albers, N., Hiort, O., Bettendorf, M., Wölfle, J., Klingmüller, D. (2000). Basal inhibin B and the testosterone response to human chorionic gonadotropin correlate in prepubertal boys. The Journal of Clinical Endocrinology & Metabolism, 85(1), 134-138.
17. Lahlou, N., Bouvattier, C., Linglart, A., Rodrigue, D. & Teinturier, C. (2009). The role of gonadal peptides in clinical investigation. Paper presented at the Annales de Biologie Clinique.
18. Lasala, C., Carré-Eusèbe, D., Picard, J.Y., & Rey, R. (2004). Subcellular and molecular mechanisms regulating anti-Müllerian hormone gene expression in mammalian and nonmammalian species. DNA and cell biology, 23(9), 572-585.
19. Lee, M.M., Donahoe, P.K., Silverman, B.L., Hasegawa, T., Hasegawa, Y., Gustafson, M.L., MacLaughlin, D.T. (1997). Measurements of serum Müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. New England Journal of Medicine, 336(21), 1480-1486.
20. Lee, P.A., Gollenberg, A. L., Hediger, M.L., Himes, J.H., Zhang, Z. & Louis, G.M.B. (2010). Luteinizing hormone, testosterone and inhibin B levels in the peripubertal period and racial/ethnic differences among boys aged 6–11 years: analyses from NHANES III, 1988–1994. Clinical endocrinology, 73(6), 744-751.
21. Lucas-Herald, A.K., Kyriakou, A., Alimussina, M., Guaragna-Filho, G., Diver, L.A., McGowan, R., Ahmed, S.F. (2020). Serum anti-Müllerian hormone in the prediction of response to hCG stimulation in children with DSD. The Journal of Clinical Endocrinology & Metabolism, 105(5), 1608-1616.
22. Majumdar, I. & Mazur, T. (2018). Management of Infants Born with Disorders/Differences of Sex Development Pediatric Endocrinology (pp. 617-639): Springer.
23. Mekkawy, M.K., Kamel, A.K., Dessouky, N., Elgharbawy, M. & Mazen, I. (2019). Cytogenetic Spectrum of Ovotesticular Difference of Sex Development (OT DSD) among a Large Cohort of DSD Patients and Literature Review. Sexual Development, 13(5-6), 221-227.
24. Ohnuma, K., Kaneko, H., Noguchi, J., Kikuchi, K., Ozawa, M. & Hasegawa, Y. (2007).Production of inhibin A and inhibin B in boars: changes in testicular and circulating levels of dimeric inhibins and characterization of inhibin forms during testis growth. Domestic animal endocrinology, 33(4), 410-421.
25. Raivio, T., Wikström, A.M., & Dunkel, L. (2007). Treatment of gonadotropin-deficient boys with recombinant human FSH: long-term observation and outcome. European Journal of Endocrinology, 156(1), 105-111.
26. Rey, R.A. & Grinspon, R. P. (2011). Normal male sexual differentiation and aetiology of disorders of sex development. Best Practice & Research Clinical Endocrinology & Metabolism, 25(2), 221-238.
27. Szarras-Czapnik, M., Gajewska, M., Ksiazyk, J., Janas, R. & Ginalska-Malinowska, M. (2006). Anti-Müllerian hormone (AMH) measurements in the assessment of testicular function in prepubertal boys and in sexual differentiation disorders. Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego: organ Polskiego Towarzystwa Endokrynologow Dzieciecych, 12(3), 195-199.
28. Young, J., Chanson, P., Salenave, S., Noël, M., Brailly, S., sO’Flaherty, M.N., Rey, R. (2005). Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. The Journal of Clinical Endocrinology & Metabolism, 90(2), 724-728.